Dmitry Balyasny’s Estee Lauder EL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.3M Buy
35,600
+18,600
+109% +$1.69M ﹤0.01% 1641
2026
Q2
$1.34M Sell
17,000
-279,200
-94% -$22.6M ﹤0.01% 2044
2026
Q1
$21.3M Buy
296,200
+226,900
+327% +$23.2M 0.03% 665
2025
Q4
$7.26M Sell
69,300
-27,200
-28% -$2.64M 0.01% 1199
2025
Q3
$8.5M Sell
96,500
-27,200
-22% -$2.42M 0.01% 1132
2025
Q2
$10M Buy
123,700
+93,500
+310% +$6.01M 0.02% 967
2025
Q1
$1.99M Sell
30,200
-28,400
-48% -$2.05M ﹤0.01% 1703
2024
Q4
$4.39M Sell
58,600
-2,500
-4% -$197K 0.01% 1342
2024
Q3
$6.09M Sell
61,100
-2,300
-4% -$218K 0.01% 1183
2024
Q2
$6.75M Buy
63,400
+50,900
+407% +$6.68M 0.01% 1038
2024
Q1
$1.93M Buy
+12,500
New +$1.77M ﹤0.01% 1550
2014
Q3
– Sell
-50,000
Closed -$3.71M – 746
2014
Q2
$3.71M Buy
+50,000
New +$3.67M 0.04% 439
2014
Q1
– Sell
-100,000
Closed -$7.53M – 587
2013
Q4
$7.53M Buy
+100,000
New +$7.24M 0.1% 250

Other funds holding EL

Dmitry Balyasny's EL Position: Q3 2026 in Review

Dmitry Balyasny increased its Estee Lauder (EL) stake by 1,857% in Q3 2026, buying an estimated $78.4M and bringing the position to 907,532 shares worth $84.2M. The position accounts for 0.1% of the portfolio, ranked #216.

Dmitry Balyasny first reported a position in EL in Q3 2013 and has held it in 31 quarters since. The position peaked at $110M in Q1 2017. 873 funds tracked by Wall St. Rank hold EL as of Q3 2026.

  • Dmitry Balyasny held 907,532 shares of Estee Lauder worth $84.2M as of Q3 2026.
  • Dmitry Balyasny bought 861,149 Estee Lauder shares in Q3 2026, an estimated $78.4M.
  • Estee Lauder made up 0.1% of Dmitry Balyasny's portfolio in Q3 2026, its #216 holding.
  • Dmitry Balyasny first reported a position in Estee Lauder in Q3 2013 and has held it in 31 quarters since.
  • Dmitry Balyasny's Estee Lauder position peaked at $110M in Q1 2017.
  • 873 funds tracked by Wall St. Rank held Estee Lauder as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.